Myokines in myogenesis and health

Recent Patents on Biotechnology

Volumn 6, Issue 3, 2012, Pages 167-171

  Henriksen, Tora ^a   Green, Charlotte ^a   Pedersen, Bente Klarlund ^a  

^a Rigshospitalet   (Denmark)

Author keywords

Activity; Cytokines; Exercise; IL 6; Inactivity; Interleukins; Irisin; Metabolic diseases; Metabolism; Muscle; Muscle cells; Muscle wasting; Muscular dystrophies; Myoblasts; Myocytes; Myogenesis; Myokines; Patents; Sarcopenia; Skeletal muscle

Indexed keywords

METABOLISM; PATENTS AND INVENTIONS;

ACTIVITY; CYTOKINES; EXERCISE; IL-6; INACTIVITY; INTERLEUKIN; IRISIN; METABOLIC DISEASE; MUSCLE CELL; MUSCLE WASTING; MUSCULAR DYSTROPHY; MYOBLASTS; MYOCYTES; MYOGENESIS; MYOKINES; PATENT; SARCOPENIA; SKELETAL MUSCLE;

MUSCLE;

BRAIN DERIVED NEUROTROPHIC FACTOR; CYTOKINE; FIBROBLAST GROWTH FACTOR 21; FOLLISTATIN; FOLLISTATIN LIKE 1; GLUCAGON LIKE PEPTIDE 1; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; IRISIN; LEUKEMIA INHIBITORY FACTOR; LEUKEMIA INHIBITORY FACTOR RECEPTOR; MESSENGER RNA; MYOKINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PROTEIN KINASE B; RECOMBINANT INTERLEUKIN 6; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CELL PROLIFERATION; CYTOKINE RELEASE; DRUG LEGISLATION; DRUG RESEARCH; DRUG TARGETING; EXERCISE; GENE; HEALTH STATUS; HEART INJURY; HUMAN; IL6 GENE; IL7 GENE; MORPHOLOGICAL ADAPTATION; MUSCLE ATROPHY; MUSCLE DEVELOPMENT; MUSCLE DISEASE; MUSCLE REGENERATION; MYOPATHY; NONHUMAN; PATENT; PRIORITY JOURNAL; PROTEIN FUNCTION; TISSUE INTERACTION;

EID: 84872563191     PISSN: 18722083     EISSN: None     Source Type: Journal    
DOI: 10.2174/1872208311206030167     Document Type: Article

References (56)

1. Long A, Donelson R, Fung T. Does it matter which exercise? A randomized control trial of exercise for low back pain. Spine [Phila Pa 1976] 2004; 29(23): 2593-602.
2. Pedersen BK. The Diseasome of Physical Inactivity-and the role of myokines in muscle-fat cross talk. J Physiol 2009; 587:5559-68.
3. Walsh K. Adipokines, myokines and cardiovascular disease. Circ J 2009; 73(1): 13-8.
4. Pedersen BK, Febbraio MA. Muscle as an Endocrine Organ: Focus on Muscle-Derived Interleukin-6. Physiol Rev 2008; 88(4): 1379-406.
5. Pedersen BK, Akerstrom TC, Nielsen AR, Fischer CP. Role of myokines in exercise and metabolism. J Appl Physiol 2007; 103(3): 1093-0.
6. Pedersen BK. The anti-inflammatory effect of exercise: its role in diabetes and cardiovascular disease control. Essays Biochem 2006; 42: 105-17.
7. Pedersen BK, Febbraio MA. Muscle, exercise and obesity: skeletal muscle as a secretory organ. Nat Rev Endocrinol. 2012; 8(8): 457-65.
8. Bortoluzzi S, Scannapieco P, Cestaro A, Danieli GA, Schiaffino S. Computational reconstruction of the human skeletal muscle secretome. Proteins 2006; 62(3): 776-92.
9. Yoon JH, Yea K, Kim J, Choi YS, Park S, Lee H, et al. Comparative proteomic analysis of the insulin-induced L6 myotube secretome. Proteomics 2009; 9(1): 51-60.
10. Henningsen J, Rigbolt KT, Blagoev B, Pedersen BK, Kratchmarova I. Dynamics of the skeletal muscle secretome during myoblast differentiation. Mol Cell Proteomics 2010; 9(11): 2482-96.
11. Norheim F, Raastad T, Thiede B, Rustan AC, Drevon CA, Haugen F. Proteomic identification of secreted proteins from human skeletal muscle cells and expression in response to strength training. Am J Physiol Endocrinol Metab 2011; 301(5): E1013-E1021.
12. Fischer CP. Interleukin-6 in acute exercise and training: What is the biological relevance? Exerc Immunol Rev 2006; 12: 6-33.
13. Keller C, Steensberg A, Pilegaard H, Osada T, Saltin B, Pedersen BK, et al. Transcriptional activation of the IL-6 gene in human contracting skeletal muscle: influence of muscle glycogen content. FASEB J 2001; 15(14): 2748-50.
14. Steensberg A, Keller C, Starkie RL, Osada T, Febbraio MA, Pedersen BK. IL-6 and TNF-alpha expression in, and release from, contracting human skeletal muscle. Am J Physiol Endocrinol Metab 2002; 283(6): E1272-E1278.
15. Hiscock N, Chan MH, Bisucci T, Darby IA, Febbraio MA. Skeletal myocytes are a source of interleukin-6 mRNA expression and protein release during contraction: evidence of fiber type specificity. FASEB J 2004; 18(9): 992-4.
16. Steensberg A, Van HG, Osada T, Sacchetti M, Saltin B, Klarlund PB. Production of interleukin-6 in contracting human skeletal muscles can account for the exercise-induced increase in plasma interleukin-6. J Physiol 2000; 529 (Pt 1): 237-42.
17. De Rossi M, Bernasconi P, Baggi F, de Waal MR, Mantegazza R. Cytokines and chemokines are both expressed by human myoblasts: possible relevance for the immune pathogenesis of muscle inflammation. Int Immunol 2000; 12(9): 1329-35.
18. Bartoccioni E, Michaelis D, Hohlfeld R. Constitutive and cytokineinduced production of interleukin-6 by human myoblasts. Immunol Lett 1994; 42(3): 135-8.
19. Keller C, Hellsten Y, Steensberg A, Pedersen BK. Differential regulation of IL-6 and TNF-alpha via calcineurin in human skeletal muscle cells. Cytokine 2006; 36(3-4): 141-7.
20. Serrano AL, Baeza-Raja B, Perdiguero E, Jardi M, Munoz-Canoves P. Interleukin-6 is an essential regulator of satellite cell-mediated skeletal muscle hypertrophy. Cell Metab 2008; 7(1): 33-44.
21. Haugen F, Norheim F, Lian H, Wensaas AJ, Dueland S, Berg O, et al. IL-7 is expressed and secreted by human skeletal muscle cells. Am J Physiol Cell Physiol 2010; 298(4): C807-C816.
22. Green CJ, Pedersen M, Pedersen BK, Scheele C. Elevated NFkappaB Activation is Conserved in Human Myocytes Cultured from Obese Type 2 Diabetics and Attenuated by AMP-activated Protein Kinase. Diabetes. 2011; 60(11): 2810-9.
23. Ellingsgaard H, Hauselmann I, Schuler B, Eppler E, Meier D, Bouzakri K, et al. Interleukin-6 enhances insulin secretion by increasing L cell and beta cell glucagon-like peptide-1 secretion. Nat Med. 2011; 17(11): 1481-9.
24. Scheele C, Nielsen S, Kelly M, Broholm C, Nielsen AR, Taudorf S, et al. Satellite cells derived from obese humans with type 2 diabetes and differentiated into myocytes in vitro exhibit abnormal response to IL-6. PLoS One 2012; 7(6): e39657.
25. Tsujinaka T., Ebisui C., Fujita J.: Method for inhibiting muscle protein proteolysis with antibodies to Interleukin-6 receptor. US6261560 (2001).
26. Jansson J.A., Stenlof K., Wallenius V., Wallenius K.: Use of Interleukin-6. US20030129160 (2003).
27. Bostrom P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC, et al. A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 2012; 481: 463-8.
28. Lin J, Handschin C, Spiegelman BM. Metabolic control through the PGC-1 family of transcription coactivators. Cell Metabolism 2005; 1(6): 361-70.
29. Wenz T, Rossi SG, Rotundo RL, Spiegelman BM, Moraes CT. Increased muscle PGC-1alpha expression protects from sarcopenia and metabolic disease during aging. Proc Natl Acad Sci U S A 2009; 106(48): 20405-10.
30. Pedersen BK. A muscular twist on the fate of fat. N Engl J Med 2012; 366(16): 1544-5.
31. Izumiya Y, Hopkins T, Morris C, Sato K, Zeng L, Viereck J, et al. Fast/Glycolytic muscle fiber growth reduces fat mass and improves metabolic parameters in obese mice. Cell Metab 2008; 7(2): 159-72.
32. Ouchi N, Oshima Y, Ohashi K, Higuchi A, Ikegami C, Izumiya Y, et al. Follistatin-like 1, a secreted muscle protein, promotes endothelial cell function and revascularization in ischemic tissue through a nitric-oxide synthase-dependent mechanism. J Biol Chem 2008; 283(47): 32802-11.
33. Oshima Y, Ouchi N, Sato K, Izumiya Y, Pimentel DR, Walsh K. Follistatin-like 1 is an Akt-regulated cardioprotective factor that is secreted by the heart. Circulation 2008; 117(24): 3099-108.
34. Izumiya Y, Bina HA, Ouchi N, Akasaki Y, Kharitonenkov A, Walsh K. FGF21 is an Akt-regulated myokine. FEBS Lett 2008; 582(27): 3805-10.
35. Hojman P, Pedersen M, Nielsen AR, Krogh-Madsen R, Yfanti C, Akerstrom T, et al. Fibroblast growth factor-21 is induced in human skeletal muscles by hyperinsulinemia. Diabetes 2009; 58(12): 2797-801.
36. Walsh K., Oshima Y., Ouchi N.: Metabolic and Cardioprotection by the Myokine Follistatin-Like 1 Polypeptide. US20100228717 (2010).
37. Hirsch R., Marinov A.D., Wilson D.C.: Immunomodulation of Inflammatory Conditions Utilizing Follistatin-Like Protein-1 and Agents That Bind Thereto. US7972599 (2011).
38. Hirsch R.: Fstl-1 as a Biomarker of Inflammation. US20110045507 (2011).
39. Potthoff MJ, Inagaki T, Satapati S, Ding X, He T, Goetz R, et al. FGF21 induces PGC-1alpha and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response. Proc Natl Acad Sci U S A 2009; 106(26): 10853-8.
40. Domouzoglou EM, Maratos-Flier E. Fibroblast growth factor 21 is a metabolic regulator that plays a role in the adaptation to ketosis. Am J Clin Nutr 2011; 93(4): 901S-5.
41. Wartiovaara A., Tyynismaa H., Raimundo N.D.N.: Dysfunction of the Mitochondrial respiratory Chain, Methods for Diagnosis, Treatment and Follow-Up. US20120064091 (2012).
42. Broholm C, Mortensen OH, Nielsen S, Akerstrom T, Zankari A, Dahl B, et al. Exercise induces expression of leukaemia inhibitory factor in human skeletal muscle. J Physiol 2008; 586(8): 2195-201.
43. Broholm C, Laye MJ, Brandt C, Vadalasetty R, Pilegaard H, Pedersen BK, et al. LIF is a contraction-induced myokine stimulating human myocyte proliferation. J Appl Physiol 2011; 111(1): 251-9.
44. Horsley V, Jansen KM, Mills ST, Pavlath GK. IL-4 acts as a myoblast recruitment factor during mammalian muscle growth. Cell 2003; 113(4): 483-94.
45. Lafreniere JF, Mills P, Bouchentouf M, Tremblay JP. Interleukin-4 improves the migration of human myogenic precursor cells in vitro and in vivo. Exp Cell Res 2006; 312(7): 1127-41.
46. Huang Z, Chen X, Chen D. Myostatin: a novel insight into its role in metabolism, signal pathways, and expression regulation. Cell Signal 2011; 23(9): 1441-6.
47. McFarlane C, Hui GZ, Amanda WZ, Lau HY, Lokireddy S, Xiaojia G, et al. Human myostatin negatively regulates human myoblast growth and differentiation. Am J Physiol Cell Physiol 2011; 301(1): C195-C203.
48. Yamada M, Tatsumi R, Yamanouchi K, Hosoyama T, Shiratsuchi S, Sato A, et al. High concentrations of HGF inhibit skeletal muscle satellite cell proliferation in vitro by inducing expression of myostatin: a possible mechanism for reestablishing satellite cell quiescence in vivo. Am J Physiol Cell Physiol 2010; 298(3): C465-C476.
49. Yang W, Zhang Y, Li Y, Wu Z, Zhu D. Myostatin induces cyclin D1 degradation to cause cell cycle arrest through a phosphatidylinositol 3-kinase/AKT/GSK-3 beta pathway and is antagonized by insulin-like growth factor 1. J Biol Chem 2007; 282(6): 3799-808.
50. Trendelenburg AU, Meyer A, Rohner D, Boyle J, Hatakeyama S, Glass DJ. Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size. Am J Physiol Cell Physiol 2009; 296(6): C1258-C1270.
51. Pedersen BK, Pedersen M, Krabbe KS, Bruunsgaard H, Matthews VB, Febbraio MA. Role of exercise-induced brain-derived neurotrophic factor production in the regulation of energy homeostasis in mammals. Exp Physiol 2009; 94(12): 1153-60.
52. Quinn LS, Haugk KL, Grabstein KH. Interleukin-15: a novel anabolic cytokine for skeletal muscle. Endocrinology 1995; 136(8): 3669-72.
53. Mortensen OH, Andersen K, Fischer C, Nielsen AR, Nielsen S, Akerstrom T, et al. Calprotectin is released from human skeletal muscle tissue during exercise. J Physiol 2008; 586(14): 3551-62.
54. Hojman P, Brolin C, Gissel H, Brandt C, Zerahn B, Pedersen BK, et al. Erythropoietin over-expression protects against diet-induced obesity in mice through increased fat oxidation in muscles. PLoS One 2009; 4(6): e5894.
55. Hojman P, Dethlefsen C, Brandt C, Hansen J, Pedersen L, Pedersen BK. Exercise-induced muscle-derived cytokines inhibit mammary cancer cell growth. Am J Physiol Endocrinol Metab 2011; 301(3): E504-E510.
56. Hamrick MW. A role for myokines in muscle-bone interactions. Exerc Sport Sci Rev 2011; 39(1): 43-7.